Active metronomic vinorelbine schedules decrease plasma interleukin-2 levels in mice with Lewis lung carcinoma

J Chemother. 2021 May;33(3):198-202. doi: 10.1080/1120009X.2020.1819069. Epub 2020 Sep 15.

Abstract

The aim of our study was to investigate the effects of metronomic vinorelbine (mVNR) in a tumor model of Lewis Lung (LL) cancer in immunocompetent C57BL/6 mice, looking at the plasma levels of interleukin-2 (IL-2) and interleukin-8 (IL-8). mVNR caused a concentration-dependent antiproliferative effect in vitro on LL/2 cells. The in vivo experiment showed the significant antitumor effects of mVNR at the dose of 4 mg/Kg and 5 mg/Kg, 3 times/week, and the significant dose-dependent decrease of IL-2 concentrations in plasma samples. Conversely, such an effect was not observed for IL-8. A significant decrease in microvessel density was also found at both the active mVNR doses. In conclusion, our study confirmed the activity of mVNR in an immunocompetent model of lung carcinoma and suggest multiple mechanisms of action, including the modulation of IL-2 levels.

Keywords: Lewis Lung carcinoma; interleukine-2; interleukine-8; metronomic chemotherapy; mice; vinorelbine.

MeSH terms

  • Animals
  • Antineoplastic Agents, Phytogenic / administration & dosage*
  • Antineoplastic Agents, Phytogenic / pharmacology*
  • Carcinoma, Lewis Lung / drug therapy*
  • Cell Line, Tumor
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Interleukin-2 / biosynthesis
  • Interleukin-8 / biosynthesis
  • Lung Neoplasms / drug therapy*
  • Mice
  • Mice, Inbred C57BL
  • Random Allocation
  • Vinorelbine / administration & dosage*
  • Vinorelbine / adverse effects
  • Vinorelbine / pharmacology*

Substances

  • Antineoplastic Agents, Phytogenic
  • Interleukin-2
  • Interleukin-8
  • Vinorelbine